In recent years, endocrine disrupting chemicals have gained interest in human
physiopathology and more and more studies aimed to explain how these chemicals …

Pituitary adenomas are one of the most frequent intracranial tumors and occur with a
prevalence of approximately 1: 1000 in the developed world. Pituitary adenomas have a …

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs
in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and …

Context: Familial isolated pituitary adenoma (FIPA) due to aryl hydrocarbon receptor
interacting protein (AIP) gene mutations is an autosomal dominant disease with incomplete …

Cyclooxygenase-2 (COX-2) is associated with breast tumour progression. Clinical and
molecular studies implicate human epidermal growth factor receptor 2 (HER2) in the …

Giant prolactinomas are rare tumours, representing only 2–3% of all prolactin (PRL)-
secreting tumours and raising special diagnostic and therapeutic challenges. Based on …

Familial isolated pituitary adenoma (FIPA) is an autosomal dominant condition with variable
genetic background and incomplete penetrance. Germline mutations of the aryl hydrocarbon …

Gigantism results when a growth hormone–secreting pituitary adenoma is present before
epiphyseal fusion. In 1909, when Harvey Cushing examined the skeleton of an Irish patient …

Background Aryl hydrocarbon receptor interacting protein (AIP) mutations (AIPmut) cause
aggressive pituitary adenomas in young patients, usually in the setting of familial isolated …

Familial pituitary adenomas can occur in MEN1 and Carney complex, as well as in the
recently characterized familial isolated pituitary adenoma (FIPA) syndrome. FIPA is an …